ACOG vs ACIU vs PRAX vs SAVA vs IQV

For growth investors, IQVIA Holdings Inc.

(IQV) is the stronger pick with 5. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). IQVIA Holdings Inc. (IQV) offers the better valuation at 23. 1x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Alpha Cognition Inc. Common Stock (ACOG) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alpha Cognition Inc.

Common Stock (ACOG) delivered a total return of -11. 3%, compared to -87. 8% for Cassava Sciences, Inc. (SAVA). Over 10 years, the gap is even starker: IQV returned +177. 5% versus ACIU's -85. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), IQVIA Holdings Inc.

(IQV) is the lower-risk stock at 1. 16β versus Cassava Sciences, Inc. 's 1. 92β — meaning SAVA is approximately 65% more volatile than IQV relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IQVIA Holdings Inc.

(IQV) is pulling ahead at 5. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -37. 3% for AC Immune S. A.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -1971. 6% for AC Immune S. A. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -1927. 3% for ACIU. At the gross margin level — before operating expenses — ACIU leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACIU: 203.

0% to $7. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, IQVIA Holdings Inc.

(IQV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 16), +177. 5% 10Y return). Cassava Sciences, Inc. (SAVA) carries a higher beta of 1. 92 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IQV: +177. 5%, SAVA: -38. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ACOG (Financial Services) and ACIU (Healthcare) and PRAX (Healthcare) and SAVA (Healthcare) and IQV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.